Statements (56)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
6
|
| gptkbp:bfsParent |
gptkb:artemisinin-based_therapies
|
| gptkbp:activities |
inhibits heme polymerization
|
| gptkbp:appointed_by |
oral tablet
|
| gptkbp:approves |
gptkb:2007
gptkb:China gptkb:Monarch other Southeast Asian countries |
| gptkbp:brand |
gptkb:Piperaquine
|
| gptkbp:can_be_used_with |
gptkb:dihydroartemisinin
|
| gptkbp:category |
gptkb:C
|
| gptkbp:clinical_trial |
Phase II
Phase III second-line treatment first-line treatment |
| gptkbp:contraindication |
severe liver disease
severe renal impairment hypersensitivity to piperaquine |
| gptkbp:developed_by |
Chinese pharmaceutical companies
|
| gptkbp:dissolved |
poorly soluble in water
|
| gptkbp:duration |
3 days
7 days |
| https://www.w3.org/2000/01/rdf-schema#label |
piperaquine
|
| gptkbp:ingredients |
C19 H22 Cl2 N2 O
|
| gptkbp:interacts_with |
antacids
certain antibiotics antifungal medications |
| gptkbp:is_atype_of |
P01 B E02
|
| gptkbp:is_available_on |
generic drug
|
| gptkbp:is_effective_against |
high against Plasmodium falciparum
high against Plasmodium vivax |
| gptkbp:is_often_used_in |
gptkb:artesunate
|
| gptkbp:is_used_for |
treatment of malaria
|
| gptkbp:lifespan |
approximately 10 days
|
| gptkbp:marketed_as |
gptkb:Piperaquine_phosphate
|
| gptkbp:metabolism |
liver
|
| gptkbp:packaging |
blister packs
|
| gptkbp:provides_information_on |
WHO recommendations
CDC guidelines |
| gptkbp:research_focus |
pharmacokinetics
combination therapies safety profile malaria resistance |
| gptkbp:rounds |
urine
|
| gptkbp:safety_features |
required during treatment
|
| gptkbp:side_effect |
gptkb:fandom
dizziness headache nausea vomiting thrombocytopenia leukopenia QT prolongation |
| gptkbp:storage |
room temperature
|
| gptkbp:type_of |
100912-21-4
|